The Bone Density Stack: Calcium, Vitamin D, K2, and Magnesium
Calcium and vitamin D do not prevent fractures or falls in community-dwelling adults who are not deficient. A 2026 BMJ meta-analysis of 69 trials and 153,902 adults not on an osteoporosis drug found little to no effect: vitamin D fracture risk ratio 1.00 (95% CI 0.95 to 1.06, high certainty), calcium 0.91 (0.81 to 1.01, moderate certainty), and the combination 0.91 (0.84 to 0.99, high certainty), which the authors judged not a meaningful absolute benefit (Massé et al., PMID 42161415). Falls were the same story. Vitamin D still treats deficiency. Calcium still fills a dietary gap up to the RDA, and it does not earn a fracture claim. The K2 finding is a separate bone-density trial, not a fracture trial: MK-7 at 180 mcg/day improved spine and femoral-neck density over three years in postmenopausal women. Resistance training and adequate protein still do more than any pill. In established osteoporosis this stack is not a treatment.
Bone density supplementation is poorly understood by most people who take it. The biggest gains come from resistance training and adequate protein, not from calcium pills. Calcium and vitamin D do not prevent fractures or falls in community-dwelling adults who are not deficient (Massé 2026, below). What remains is narrower: calcium only to close a gap under the RDA, vitamin D to treat a measured deficiency, vitamin K2 for the bone-density trial described below, and magnesium as a cofactor. These are not a fracture-prevention stack.
Layer 1: Calcium — To Meet, Not Exceed, the RDA
The most important calcium fact is that more is not better, and that a supplement does not prevent fractures in community-dwelling adults who are not deficient. The RDA is 1,000 mg daily for adults under 50, 1,200 mg for women over 50 and men over 70. If you reach that from diet, supplement zero. Massé et al. (BMJ 2026; 69 trials, 153,902 adults not on an osteoporosis drug; PMID 42161415; doi:10.1136/bmj-2025-088050) found a fracture risk ratio of 0.91 for calcium alone (95% CI 0.81 to 1.01, moderate certainty) and 0.91 for calcium plus vitamin D (0.84 to 0.99, high certainty). The authors judged the absolute differences not clinically meaningful, and they found little to no effect on falls. Most participants were community-dwelling. Use calcium citrate (better absorption fasted or in adults on PPIs) at 500 mg per dose only for a dietary gap; never take more than 600 mg of supplemental calcium at once. See our calcium harm/benefit analysis.
Layer 2: Vitamin D3 — Dose to a Serum Level, Not a Daily IU Target
Vitamin D3 is the supplement used to correct deficiency and to support calcium absorption. It does not prevent falls or fractures in community-dwelling adults who are not deficient. The VITAL trial of 25,871 adults on 2,000 IU a day found no reduction in fractures in people who were already mostly replete. The 2026 BMJ review (PMID 42161415) found a vitamin D fracture risk ratio of 1.00 (95% CI 0.95 to 1.06, high certainty; 36 trials, 92,045 people) and little to no effect on falls. Test 25-OH-D and treat a deficiency. Do not use a fixed high dose as fall prevention. See our vitamin D dose guide.
Layer 3: Vitamin K2 (MK-7), 100–180 mcg Daily
Vitamin K2 activates osteocalcin, the protein that binds calcium to bone matrix. Without sufficient K2, osteocalcin remains undercarboxylated and calcium goes preferentially to soft tissues (arteries) instead of bone. The strongest RCT evidence is Knapen 2013, a three-year trial in postmenopausal women showing that MK-7 180 mcg daily improved both lumbar spine and femoral neck BMD versus placebo. The Japanese pharmaceutical dose for osteoporosis (MK-4 at 45 mg daily) has stronger fracture-prevention data but at a far higher dose than typical supplements provide. MK-7 at 100–180 mcg daily is the practical compromise. Avoid in adults on warfarin without anticoagulation input. See the K2 evidence overview.
Layer 4: Magnesium, 250–350 mg Elemental Daily
Magnesium is involved in roughly 60% of total body magnesium being stored in bone, and serum magnesium correlates positively with BMD in observational cohorts. RCT evidence is thinner than for the first three layers but a 2014 trial in postmenopausal women showed that magnesium oxide 1,830 mg daily for 30 days improved BMD modestly versus placebo. The mechanism includes activation of vitamin D's 1-alpha-hydroxylase, regulation of PTH, and direct effects on osteoblast function. Magnesium glycinate or citrate at 250–350 mg elemental daily is reasonable; do not exceed 350 mg without a check on renal function. See our magnesium form comparison.
What NOT to Add
Strontium ranelate had positive BMD trial data but was withdrawn in most jurisdictions due to cardiovascular and skin-toxicity signals; the supplement form (strontium citrate) has no equivalent fracture evidence and inflates DXA artifactually because strontium has higher atomic number than calcium. Skip "bone broth collagen" as a bone density intervention — see our collagen review for what it actually does. Boron has weak BMD signals. For pharmacological bone density gain in established osteoporosis, denosumab, bisphosphonates, or anabolic agents like teriparatide vastly outperform any supplement combination — see the osteoporosis condition page.
How to Run the Stack and Bottom Line
Start with diet — calculate dietary calcium intake from dairy and leafy greens, supplement only the gap to the RDA. Test serum 25-OH-D and dose D3 to 30–50 ng/mL. Add K2 (MK-7) and magnesium routinely. Re-evaluate with a DXA scan every 2 years if at risk. This stack is a foundation, not a treatment. In established osteoporosis (T-score ≤ –2.5), supplements alone will not prevent fractures; pharmacotherapy plus resistance training is the standard.
Sources
- Jackson RD, LaCroix AZ, Gass M, et al. "Calcium plus vitamin D supplementation and the risk of fractures." NEJM, 2006;354(7):669-683. PMID: 16481635. DOI: 10.1056/NEJMoa055218.
- Bolland MJ, Avenell A, Baron JA, et al. "Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis." BMJ, 2010;341:c3691. PMID: 20671013. DOI: 10.1136/bmj.c3691.
- LeBoff MS, Chou SH, Ratliff KA, et al. "Supplemental vitamin D and incident fractures in midlife and older adults (VITAL)." NEJM, 2022;387(4):299-309. PMID: 35939577. DOI: 10.1056/NEJMoa2202106.
- Knapen MHJ, Drummen NE, Smit E, Vermeer C, Theuwissen E. "Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women." Osteoporosis International, 2013;24(9):2499-2507. PMID: 23525894. DOI: 10.1007/s00198-013-2325-6.
- Aydin H, Deyneli O, Yavuz D, et al. "Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women." Biological Trace Element Research, 2010;133(2):136-143. PMID: 19488681. DOI: 10.1007/s12011-009-8416-8.
- Tai V, Leung W, Grey A, Reid IR, Bolland MJ. "Calcium intake and bone mineral density: systematic review and meta-analysis." BMJ, 2015;351:h4183. PMID: 26420598. DOI: 10.1136/bmj.h4183.
- Massé O, Mercurio CM, Dupuis S, et al. "Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis." BMJ, 2026;393:e088050. PMID: 42161415. DOI: 10.1136/bmj-2025-088050.